Ostarine belongs to non-steroidal selective androgen receptor modulator limited strictly to preclinical laboratory pharmacological research rather than approved human therapeutic drug or dietary supplement raw material. It binds selectively to androgen receptor and triggers anabolic effects on skeletal muscle and bone tissue with weak androgenic activity on reproductive organs, which makes it a common research reagent for multiple preclinical study fields. Primary research directions cover sarcopenia and disease-caused muscle wasting research, using aged rodents and cachexia animal models to explore its efficacy on increasing lean muscle mass, inhibiting muscle degradation and improving body weight loss caused by malignant tumor and chronic wasting diseases. It is also widely used in osteoporosis pharmacodynamic tests to verify its function of elevating bone mineral density and inhibiting excessive bone resorption without obvious prostate proliferation side effects of traditional androgen drugs. Besides, the compound is used in cellular level research to study androgen receptor signaling pathway and guide structural modification of new anti-wasting candidate medicines. Listed as banned doping substance by global anti-doping institutions, unauthorized human intake for fitness or athletic performance enhancement violates drug control regulations in most regions.
GHS hazard grade is Warning with H315 skin irritation and H319 severe eye irritation labels, full personal protective equipment must be worn throughout all experimental operations. Operators need nitrile gloves, anti-splash safety goggles and dust-proof lab coat during weighing and liquid preparation to prevent dust inhalation, prolonged skin contact and accidental oral ingestion. All residual solids and waste solvent containing this compound must be classified as hazardous waste and processed by certified professional waste treatment agencies in accordance with local environmental rules instead of regular domestic garbage disposal. Available animal toxicology data shows continuous high-dose administration suppresses endogenous testosterone production and causes endocrine disorder, fatigue and reduced libido in experimental animals. Long-term repeated dosing may bring mild liver metabolic pressure and potential cardiovascular risks, while comprehensive long-term carcinogenicity and reproductive toxicity data have not been fully confirmed. Dosing is prohibited in all experiments involving pregnant laboratory animals for unknown developmental toxicity risks. Store separately from strong oxidants and strong acids to avoid unwanted chemical deterioration during long-term preservation.
